Anti-CD7 Chimeric Antigen Receptor T-Cell therapy(Bioceltech Therapeutics)

N/A

Report date: 2022/09/28 10:43:11

Base Information

Drug NameAnti-CD7 Chimeric Antigen Receptor T-Cell therapy(Bioceltech Therapeutics)
Drug Alias NameAnti-CD7 chimeric antigen receptor T cell therapy - Bioceltech TherapeuticsBT-007 CD7 CAR-T cells - Bioceltech TherapeuticsBT-007
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGracell Biotechnologies (Shanghai) Co LtdBioceltech Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBioceltech Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A